Remaining questions surrounding HER2-low breast cancer – how low can you go?
Paolo Tarantino • 8 Dec 2022
DESTINY-Breast04: T-DXd provides significant improvement in OS + PFS in HER2-low mBC
Hope Rugo • 5 Jun 2022
Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Keep up to date with all the latest news with our monthly newsletter